Nathan Johnson, PhD

Investigator, H3 Biomedicine

Boston

Nathan Johnson is currently a Investigator at H3 Biomedicine. H3 Biomedicine is a privately held biopharmaceutical company focused on the discovery and early development of novel, targeted anti-cancer compounds for the unmet needs of genetically defined patient populations. H3 has leveraged its integrated expertise in genomics, tumor biology, bioinformatics and innovative synthetic organic chemistry to create an integrated drug development ecosystem to deliver patient-based, genomics-driven, small molecule drugs.

As a former Research Scientist at Harvard Medical School (HMS) and Dana-Farber Cancer Institute (DFCI), he was responsible for merging his biological expertise with computer science and data science in order to achieve breakthroughs in breast cancer and Alzheimer’s therapeutic research. He used AI in order to drive new insight into how to recognize relevant patterns that would be difficult to impossible without it. He has been involved in research for almost 15 years across a number of challenges for diseases such as Duchenne Muscular Dystrophy, Polycystic Kidney Disease, Acute Lymphoblastic Leukemia, and on how to prevent parasites from infecting soybeans. Prior to pursuing his graduate studies, he worked as a microbiologist testing food products such as Hershey's, baby formula, and meat for pathogens. He holds a BS in Biology with a minor in Chemistry from Evangel University in Springfield, MO, an MS in Biomedical Sciences from the University of Missouri in Columbia, MO, and a Ph.D. in Bioinformatics and Computational Biology from Worcester Polytechnic Institute (WPI) in Worcester, MA.